Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01601236 · ClinicalTrials.gov registry record · Phase 2
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Phase 2 study of Diabetic Nephropathy, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 10
- Study locations
NCT01601236 is a Phase 2 study of Diabetic Nephropathy that has completed, run by Mallinckrodt. The registered enrollment target is 34 participants, below the 11,427-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT01601236, a Phase 2 study of Diabetic Nephropathy, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 10
- Study locations
Study Summary
This Phase 2A study is an adaptive design pilot study investigating the efficacy and safety of daily Acthar administration in diabetic patients with nephropathy and proteinuria. Patients with type 1 diabetes mellitus (T1DM) or T2DM who currently take insulin will be enrolled and randomized into 6 study groups and will be treated with either Acthar or Placebo for 36 weeks, followed by a 4 week dose taper, and a 12 week observation period. The study will compare three dose regimens of Acthar (8 U \[0.1 mL\], 16 U \[0.2 mL\], and 32 U \[0.4 mL\]) to equivalent volumes of Placebo to ensure the double-blind nature of the study. Insulin-requiring patients are being enrolled to aid compliance with the daily SC administration of study medication and to allow for ease of blood glucose control by adjustment of current insulin therapy in the event of glycemic excursions. Routine safety measures, including glycemic control, will be monitored throughout the study. The adaptive design component of the study allows for the re-assignment of the high dose group to the mid dose group if unacceptable toxicity is noted as per study protocol in the high dose group. Efficacy will be assessed by monitoring serum creatinine, calculated eGFR, and proteinuria (via urinary protein to creatinine ratio \[PCR\]). Serum cortisol concentration and additional biomarkers in blood and urine will also be monitored.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Repository Corticotropin Injection
Study Locations (10)
Texas
- Questcor Investigational Site - Greenville
- Questcor Investigational Site - Houston
- Questcor Investigational Site - San Antonio
Florida
- Questcor Investigational Site - Cooper City
- Questcor Investigational Site - Miami Springs
California
- Questcor Investigational Site - Roseville
New York
- Questcor Investigational Site - The Bronx
Ohio
- Questcor Investigational Site - Columbus
Pennsylvania
- Questcor Investigational Site - Bethlehem
Tennessee
- Questcor Investigational Site - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-05 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01601236
The ClinicalTrials.gov registry entry for NCT01601236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 11,427-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01601236 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT01601236 about?
NCT01601236 is a clinical study titled "Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients". This Phase 2A study is an adaptive design pilot study investigating the efficacy and safety of daily Acthar administration in diabetic patients with nephropathy and proteinuria. Patients with type 1 diabetes mellitus (T1DM) or T2DM who currently take insulin will be enrolled and randomized into 6 st...
What is the current status of trial NCT01601236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2012-05. Estimated completion is 2016-03.
What conditions does trial NCT01601236 study?
This clinical trial studies the following conditions: Diabetic Nephropathy.
What interventions are being tested in trial NCT01601236?
The interventions under investigation include: Placebo (DRUG), Repository Corticotropin Injection (DRUG).
Who is sponsoring clinical trial NCT01601236?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01601236 being conducted?
This trial has 10 study locations across California, Florida, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
COMPLETED · Phase 2
-
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
COMPLETED · Phase 2
-
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
COMPLETED · Phase 2
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RECRUITING
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.